Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates to provide potassium ions and chloride ions. Potassium repletion corrects hypokalemia and associated disorders.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Treatment or prevention of hypokalemia,Digitalis intoxication,Familial periodic paralysis (hypokalemic form),Diuretic-induced hypokalemia
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
Oral: 40-100 m Eq/day in divided doses; IV: up to 10-20 m Eq/hour via central line, max 40 m Eq/hour with continuous monitoring; not to exceed 200 m Eq/day.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Not applicable; potassium is an electrolyte regulated by homeostasis, not classic elimination half-life. Under normal renal function, serum half-life of administered potassium is approximately 2-4 hours due to rapid cellular uptake and renal excretion.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Potassium is not metabolized; it is excreted primarily by the kidneys. Approximately 90% is excreted in the urine, with the remainder in feces and sweat. Renal excretion is influenced by aldosterone.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Primarily renal (90%) as potassium ion; minimal fecal (<10%) and sweat.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Minimal; <2% bound to plasma proteins.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
0.5-0.7 L/kg; distributes primarily to intracellular compartment (98% of total body potassium is intracellular).
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Oral: 90-100% (well absorbed from gastrointestinal tract, subject to first-pass uptake by liver; bioavailability is near complete).
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
e GFR >50: no adjustment; e GFR 10-50: reduce dose by 25-50%; e GFR <10: avoid or use with extreme caution, starting at 50% of usual dose.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
No specific adjustment required for Child-Pugh A, B, or C; monitor potassium levels closely due to risk of hyperkalemia.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
Oral: 1-3 m Eq/kg/day in divided doses; IV: 0.25-0.5 m Eq/kg/hour, max 1 m Eq/kg/hour with cardiac monitoring; max daily dose 3 m Eq/kg/day.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Start at low end of adult dosing (e.g., 20 m Eq/day) and titrate slowly; monitor renal function and potassium levels frequently due to decreased renal reserve.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
Potassium chloride injection concentrate must be diluted before use. Undiluted administration can result in fatal cardiac arrest. Also, potassium supplements should not be used in patients with hyperkalemia or conditions that predispose to hyperkalemia.
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Cardiac arrest if administered too rapidly or in concentrated form,Hyperkalemia risk especially in renal impairment, diabetes, or concurrent use of ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics,Gastrointestinal irritation with oral solid formulations; use with caution in patients with esophageal compression or delayed GI transit,Monitor serum potassium and ECG during parenteral therapy,Avoid potassium chloride in patients with severe burns, crush injuries, or other conditions that lead to rapid cellular breakdown
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hyperkalemia (serum potassium >5.5 m Eq/L),Severe renal impairment with oliguria or anuria,Uncontrolled Addison's disease,Acute dehydration,Concurrent use with potassium-sparing diuretics (e.g., spironolactone, eplerenone, amiloride, triamterene),Solid oral forms in patients with conditions that delay GI transit or esophageal compression
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Avoid potassium-rich foods in excess (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados, dried fruits, salt substitutes) unless instructed by your doctor. Do not take with alcohol or excessive coffee/tea, which may affect electrolyte balance.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
Potassium chloride is not teratogenic. There is no evidence of fetal harm from oral or intravenous administration at therapeutic doses, provided maternal potassium levels are maintained within normal range. No trimester-specific risks identified; however, maternal hypokalemia or hyperkalemia can adversely affect fetal outcomes (e.g., arrhythmias, growth restriction).
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Potassium is a normal constituent of breast milk. Potassium chloride supplementation at recommended doses is considered compatible with breastfeeding. Maternal milk-to-plasma (M/P) ratio is approximately 0.1-0.3, indicating low transfer. No adverse effects in nursing infants reported.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
Dosing adjustments not required specifically due to pregnancy. However, increased plasma volume in pregnancy may dilute serum potassium; dose should be guided by serum potassium levels and clinical need. No evidence of altered pharmacokinetics requiring dose change.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
Potassium chloride is the preferred salt for replacement due to high chloride content which corrects metabolic alkalosis. Always administer IV potassium at a rate not exceeding 10-20 m Eq/hour peripherally, and 10-40 m Eq/hour centrally with continuous ECG monitoring. Never give IV potassium undiluted; maximum concentration for peripheral IV is 10 m Eq/100 m L. In severe hypokalemia (K+ < 2.5 m Eq/L), consider cardiac monitoring and admission. Oral potassium should be taken with food to minimize gastric irritation. Caution in renal impairment and with potassium-sparing diuretics or ACE inhibitors.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
Take potassium chloride with food or after a meal to prevent stomach upset.,Do not crush or chew extended-release tablets; swallow whole with a full glass of water.,Use the oral solution only if it is clear; do not mix with other drinks without asking your doctor.,Do not use salt substitutes (which contain potassium) while taking potassium supplements unless directed.,Report symptoms of high potassium levels: muscle weakness, irregular heartbeat, tingling in hands/feet, or confusion.,Keep all appointments for blood tests to monitor your potassium levels.,Store at room temperature away from moisture and heat.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE vs KAON CL, answered by our medical review team.
POTASSIUM CHLORIDE is a Electrolyte Supplement that works by Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates to provide potassium ions and chloride ions. Potassium repletion corrects hypokalemia and associated disorders.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE and KAON CL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE is: Oral: 40-100 m Eq/day in divided doses; IV: up to 10-20 m Eq/hour via central line, max 40 m Eq/hour with continuous monitoring; not to exceed 200 m Eq/day.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE is classified as Category C. Potassium chloride is not teratogenic. There is no evidence of fetal harm from oral or intravenous administration at therapeutic doses, provided maternal potassium levels are maint. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.